Related references
Note: Only part of the references are listed.Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer
P. Travis Courtney et al.
JAMA NETWORK OPEN (2021)
Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer
Hongchao Li et al.
CLINICAL DRUG INVESTIGATION (2020)
Economic burden of patients with advanced non-small-cell lung cancer receiving nivolumab versus chemotherapy in China
Qingqing Chai et al.
IMMUNOTHERAPY (2020)
Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data
Bin Wu et al.
JAMA DERMATOLOGY (2020)
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Huabin Hu et al.
FRONTIERS IN ONCOLOGY (2020)
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
S. Peters et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis
Frank Griesinger et al.
LUNG CANCER (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US
Ralph P. Insinga et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Sustainability and affordability of cancer drugs: a novel pricing model
Carin A. Uyl-de Groot et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer
Tiffany M. Yu et al.
VALUE IN HEALTH (2018)
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
Ralph P. Insinga et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Hmwe Hmwe Kyu et al.
LANCET (2018)
US drug prices should be tied to foreign prices to tackle global freeloading, says Trump
Owen Dyer
BMJ-BRITISH MEDICAL JOURNAL (2018)
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
Yixin Zhou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis
Kayode Ogungbenro et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer
Daniel A. Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources
Bin Wu et al.
ONCOTARGET (2017)
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer
Daniel A. Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
Gillian D. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial
John Hornberger et al.
LUNG CANCER (2015)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
What Is the Price Benchmark to Replace Average Wholesale Price (AWP)?
Frederic R. Curtiss et al.
JOURNAL OF MANAGED CARE PHARMACY (2010)
Share Paper
